Abbott Laboratories (Abbott Laboratories) LT-Debt-to-Total-Asset : 0.20 (As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

What is Abbott Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Abbott Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.20.

Abbott Laboratories's long-term debt to total assets ratio declined from Dec. 2022 (0.21) to Dec. 2023 (0.20). It may suggest that Abbott Laboratories is progressively becoming less dependent on debt to grow their business.

Abbott Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Abbott Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories LT-Debt-to-Total-Asset Chart

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.27

0.24

0.21

0.20

Abbott Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.20	0.20	0.20	-

Abbott Laboratories LT-Debt-to-Total-Asset Calculation

Abbott Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	14548	/	73214
	=	0.20

Abbott Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	14548	/	73214
	=	0.20

Abbott Laboratories (NYSE:ABT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Abbott Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories (Abbott Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ABT:Mexico 0Q15:UK ABL:Germany ABL:Germany ABL:Germany ABL:Germany ABT:Chile ABT:Switzerland ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Executives

Andrea F Wainer	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr.	officer: VICE PRESIDENT	C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman	director	3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone	officer: EXECUTIVE VICE PRESIDENT	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau	officer: Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady	director	50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive	officer: Senior Vice President	100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt	officer: Executive Vice President	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck	officer: Vice President, Controller	100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092